These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10465091)

  • 1. Salvage therapy in HIV-positive patients with a previous therapeutic experience with protease inhibitors. Members of the Master Group.
    Maggiolo F; Maserati R; Pan A; Castelli F; Suter F
    AIDS; 1999 Aug; 13(12):1591-2. PubMed ID: 10465091
    [No Abstract]   [Full Text] [Related]  

  • 2. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
    Vavro CL; Zimmermann AM; McClernon DR; Kehne SL; Martel LA; Valentine ME; McKinney RE
    Ann N Y Acad Sci; 2000 Nov; 918():381-5. PubMed ID: 11131731
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 4. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 8. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvage therapy studies.
    Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 11. Salvage therapy: still more intuition than data.
    Gilden D
    GMHC Treat Issues; 1999 Jan; 13(1):6-12. PubMed ID: 11366112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA
    AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients.
    Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF
    AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonnucleoside reverse transcriptase inhibitors.
    Murphy RL
    AIDS Clin Care; 1997 Oct; 9(10):75-7, 79. PubMed ID: 11364757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 19. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Another take on when to start and how to succeed.
    Friedland GH
    AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.